Journal of thrombosis and haemostasis : JTH · 2025
Factor VIII, a coagulation cofactor, is a relevant survival factor in bladder cancer cell lines.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Walker Gillian E, Borroni Ester, Haider Rida, Olgasi Cristina, Borsotti Chiara, Follenzi Antonia
Аннотация
BACKGROUND: Factor (F)VIII, an essential coagulation cofactor and independent cancer-associated thrombotic risk factor, has recently been shown to be synthesized directly by a broad profile of cancers. With evident extracoagulative functions, it remains to be understood if FVIII can play a functional role in cancer.
OBJECTIVES: Establish if FVIII plays a direct role in bladder cancer cell models.
METHODS: Bladder cancer cell lines 5637 and ECV-304 were treated with recombinant human FVIII (rFVIII) B-domain-deleted or full-length rFVIII (rFVIII-FL) in low serum conditions, where cell cycle, migration, and cell survival were assessed. Cell cycle was measured by 7-aminoactinomycin D incorporation and migration by Transwell or wound healing assays. Cell survival was assessed by crystal violet (optical density 592) and 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (optical density 570) assays. Cell adhesion was determined with integrin β1 and αV protein levels, annexin-V-FITC/7-aminoactinomycin D staining, and Bcl2 with procaspase3 levels for apoptosis. Cancer cell-derived effects were assessed by silencing FVIII using short hairpin RNA.
RESULTS: In both bladder cancer cell lines, cell cycle progression was pushed, and migration was advanced by rFVIII. More dramatic were the survival effects for rFVIII-FL, confirmed in a cell line of diverse origin, the osteosarcoma U2OS, through the maintenance of cell adhesion and inhibition of apoptosis. Further, silencing cell-derived FVIII retarded both cell cycle progression and migration. More importantly, cell survival was dramatically reduced and could be blocked by the administration of rFVIII-FL.
CONCLUSION: Overall, this investigation highlights FVIII as a relevant survival factor in bladder cancer cells and provides evidence of its role in cancer.
OBJECTIVES: Establish if FVIII plays a direct role in bladder cancer cell models.
METHODS: Bladder cancer cell lines 5637 and ECV-304 were treated with recombinant human FVIII (rFVIII) B-domain-deleted or full-length rFVIII (rFVIII-FL) in low serum conditions, where cell cycle, migration, and cell survival were assessed. Cell cycle was measured by 7-aminoactinomycin D incorporation and migration by Transwell or wound healing assays. Cell survival was assessed by crystal violet (optical density 592) and 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (optical density 570) assays. Cell adhesion was determined with integrin β1 and αV protein levels, annexin-V-FITC/7-aminoactinomycin D staining, and Bcl2 with procaspase3 levels for apoptosis. Cancer cell-derived effects were assessed by silencing FVIII using short hairpin RNA.
RESULTS: In both bladder cancer cell lines, cell cycle progression was pushed, and migration was advanced by rFVIII. More dramatic were the survival effects for rFVIII-FL, confirmed in a cell line of diverse origin, the osteosarcoma U2OS, through the maintenance of cell adhesion and inhibition of apoptosis. Further, silencing cell-derived FVIII retarded both cell cycle progression and migration. More importantly, cell survival was dramatically reduced and could be blocked by the administration of rFVIII-FL.
CONCLUSION: Overall, this investigation highlights FVIII as a relevant survival factor in bladder cancer cells and provides evidence of its role in cancer.